Salute e Benessere

The Board of Directors of Sobi exercises authorisation for repurchase of shares…

Today, the Board of Directors has resolved to exercise the repurchase authorisation for the said purpose by repurchasing all issued class C shares against payment of 100 per cent of the quotient value of the share, corresponding to approximately SEK 0.55 per share. Repurchase of the class C shares may be effected during the period 20 June – 9 November 2023. Today, the Board of Directors has resolved to exercise the repurchase authorisation for the said purpose by repurchasing all issued class…
PR Newswire
20/06/2023

uniQure announces achievement of $100 million milestone related to hemophilia B…

Milestone payment triggered by first commercial sale of HEMGENIX® in U.S. by CSL Behring uniQureN.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced the achievement of a $100 million milestone associated with the first commercial sale of HEMGENIX ®in the United States by its partner, global biotechnology leaderCSL(ASX: CSL). HEMGENIX ®(etranacogene dezaparvovec) is a one-time administered gene...
Nasdaq GlobeNewswire
20/06/2023

ADVANZ PHARMA Partners with Veeva to Set Unified Digital-First Commercial…

"Since more than doubling our sales and medical footprint with our recent acquisition of Intercept, we needed to scale field operations with a single system to increase visibility throughout the customer engagement journey," said Andy Eeckhout, global head of CRM and digital solutions at ADVANZ. "With Veeva Commercial Cloud, we have a foundation to maximize impact as we move into new markets." "Since more than doubling our sales and medical footprint with our recent…
PR Newswire
20/06/2023

Independent Proxy Advisory Firm ISS Recommends Alkermes Shareholders Vote…

ISS' Flawed Profitability Analysis Disregards 2022 Janssen Royalties ISS' Flawed Profitability Analysis Disregards 2022 Janssen Royalties Alkermes Board Believes Alex Denner's Serial Nominee Sarah Schlesinger, M.D. is Not Independent of Sarissa DUBLIN,June 20, 2023/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) (the Company) today announced that independent shareholder advisory firm Institutional Shareholder Services (ISS) has recommended that shareholders vote against the...
PR Newswire
20/06/2023

Chronic Kidney Disease Treatment Market to Reach $47.9 Billion, Globally, by…

Download Sample Copy- https://www.alliedmarketresearch.com/request-sample/107605 Download Sample Copy- https://www.alliedmarketresearch.com/request-sample/107605 Prime determinants of growth Growing prevalence of chronic kidney disease (CKD) and technological advancement drive the growth of the global Chronic Kidney Disease Treatment Market. However, the high cost of chronic kidney disease (CKD) treatment presents a significant challenge and hampers market growth. On the...
PR Newswire
20/06/2023

Chemotherapy Induced Anemia Market to Reach $5 Billion, Globally, by 2032 at…

Download Sample Copy- https://www.alliedmarketresearch.com/request-sample/10904 Download Sample Copy-https://www.alliedmarketresearch.com/request-sample/10904 Prime determinants of growth The increase in the prevalence of cancer and the surge in demand for chemotherapy-induced anemia treatment drive the growth of the global chemotherapy-induced anemia market. However, the high cost of chemotherapy-induced anemia treatments is hampering the chemotherapy-induced anemia market...
PR Newswire
20/06/2023

BioSenic presents data on its new copper-arsenic trioxide combination for…

INSIDE INFORMATIONCombining arsenic and a metal ion decreases dosage needed for therapeutic effects in preclinical chronic graft-versus-host disease and systemic sclerosis modelsMont-Saint-Guibert , Belgium , June20 th 2023 , 7 .00amCET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell repair, will present the latest data on its arsenic trioxide (ATO) platform at...
Nasdaq GlobeNewswire
20/06/2023

Digital Diabetes Management Market worth $31.3 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144725893 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144725893 Browse in-depth TOC on "Digital Diabetes Management Market" 70 - Tables 50 - Figures 150 - Pages Digital Diabetes Management Market Scope: "Continuous Glucose Monitoring (CGM) systems segment to grow at the highest CAGR during the forecast period." ...
PR Newswire
20/06/2023

Longbio Pharma Presented Positive Topline Phase 1 Results for LP-003 at ERS2023

Abstract Submission ID: 1209 Abstract Submission ID: 1209 Results: LP-003 has high IgE binding affinity (>100 fold) without off-target binding, more potent FcεRI and FcεRII/CD23 inhibition compared to omalizumab. In a randomized, double-blind, Phase I clinical study (CTR20221413), 32 healthy subjects were randomly divided into five groups to receive a single intravenous dose of 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg and 10 mg/kg respectively. Safety, pharmacokinetics, and...
PR Newswire
20/06/2023

SpliceBio Appoints David Favre, D.V.M., Ph.D., as Chief Development Officer to…

Miquel Vila-Perelló, CEO and co-founder of SpliceBio, said: "I am excited to welcome David to the SpliceBio leadership team at an exciting time of platform expansion as we begin preparations for clinical development. His extensive knowledge in gene therapy, immunology and drug development will be invaluable as he takes the lead on development of the Company's therapeutic candidates from preclinical research to the clinic. David will focus on advancing the company's lead AAV gene therapy…
PR Newswire
20/06/2023

Adcendo Appoints Experienced Drug Developer Dr. Lone H. Ottesen as Chief Medical…

Michael Pehl, Chief Executive Officer of Adcendo, said "We are delighted to welcome Lone with her extensive global oncology drug development experience to lead our ambitious, clinical development strategy and help maximize the full potential of our unique first-in-class ADC pipeline. Lone brings a distinctive blend of experience in solid tumor oncology, ADCs and biologics within early and late-stage clinical development both at biotech and large pharmaceutical companies. We are extremely…
PR Newswire
20/06/2023

Suvoda Expands Board of Directors With Addition of Clinical Trial Veteran Irena…

"Irena brings a wealth of experience and knowledge in all aspects of clinical development and is known to be a change leader and practical innovator," said Jagath Wanninayake, CEO of Suvoda. "Throughout her career, she has demonstrated a commitment to the science of clinical research, while also focusing on the human element, particularly the site and patient experience. Her unique perspective on the Suvoda board will make a significant contribution to our ability to deliver…
PR Newswire
20/06/2023

Bavarian Nordic Reports Data from a Phase 3 Clinical Trial of its VLP-Based…

Study successfully met its primary endpoints Data from second pivotal Phase 3 study in people aged 12 to 64 years expected in the third quarter 2023COPENHAGEN, Denmark, June 20, 2023– Bavarian Nordic A/S (OMX: BAVA) announced today the initial safety and immunogenicity results from a randomized, double-blind, placebo-controlled Phase 3 clinical trial of a virus-like particle (VLP)-based chikungunya virus (CHIKV) vaccine candidate CHIKV VLP (PXVX0317) in healthy adults ≥65 years of age...
Nasdaq GlobeNewswire
20/06/2023

Invitation to presentation of Essity's Half-year Report 2023

For further information, please contact:Per Lorentz, Vice President Corporate Communications, +46 733 13 30 55, per.lorentz@essity.comJohan Karlsson, Vice President Investor Relations, +46 705 11 15 81, johan.ir.karlsson@essity.com For further information, please contact: Per Lorentz, Vice President Corporate Communications, +46 733 13 30 55,per.lorentz@essity.com Johan Karlsson, Vice President Investor Relations, +46 705 11 15 81,johan.ir.karlsson@essity.com The following…
PR Newswire
20/06/2023

BVI launches FINEVISION HP, a novel hydrophobic trifocal IOL based on the FINE…

FINEVISION HP is the first patented diffractive trifocal IOL and is one of the flagship products in BVI's IOL portfolio; FINE Trifocal technology is utilized across the company's entire range of presbyopia-correcting IOLs.The Japan launch follows two key FINEVISION HP 2023 milestones: One million FINEVISION IOL implants sold worldwide and the recent completion of the FINEVISION HP IDE clinical study patient enrollment in the US.BVI expects to introduce several IOL models over the...
Nasdaq GlobeNewswire
20/06/2023

Mendus appoints NK cell pioneer Lewis Lanier to Scientific Advisory Board

MENDUS' STRENGTHENS SCIENTIFIC BASIS FOR NK CELL RESEARCH , AS LONGER-TERM PIPELINE PROGRAMCOMPLEMENTING CLINICAL-STAGE LEAD ASSETS Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced the appointment of Lewis Lanier, PhD, Professor Emeritus in Microbiology and Immunology at University of California, San Francisco (UCSF), to the Mendus' Scientific Advisory Board...
Nasdaq GlobeNewswire
20/06/2023

Press Release: Sanofi prevails in Zantac arbitration initiated by Boehringer…

Sanofi prevails inZantac arbitration initiated by Boehringer Ingelheim Arbitral tribunal dismisses claim brought by Boehringer Ingelheim (“BI”) against Sanofi for indemnification of potential liabilities related to the ongoing Zantac litigation in the U.S. ; decision is final and cannot be appealedKey U.S. federal court ruling in December 2022 found no reliable evidence that Zantac causes the alleged injuries, bolstered similar findings by FDA and EMA; tens of thousands of...
Nasdaq GlobeNewswire
20/06/2023

Idorsia has secured bridge financing in the amount of CHF 75 million

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – June20 , 2023Idorsia Ltd (SIX: IDIA) today announced that it has secured bridge financing in the amount of CHF 75 million to extend the company's cash runway until the end of July and in the meantime allow the completion of the recently announced prospective strategic transaction for its Asia Pacific (ex-China) operations, which is subject to completion of satisfactory due diligence and legal documentation...
Nasdaq GlobeNewswire
20/06/2023

NMD Pharma Reports Results from the ESTABLISH Study – an International…

NMD Pharma ReportsResults from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2 Results from the study establish , for the first time,neuromuscular junction (NMJ)transmissiondeficitas a new disease characteristic in patients with Charcot-Marie-Tooth (CMT) type 1 and 2The level of NMJ transmission deficitin patients with CMT was associated with disease...
Nasdaq GlobeNewswire
20/06/2023

Point-of-Care Glucose Testing Market to Reach $4.8 Billion, Globally, by 2032 at…

Download Sample Copy- https://www.alliedmarketresearch.com/request-sample/10820 Download Sample Copy-https://www.alliedmarketresearch.com/request-sample/10820 Prime Determinants of Growth: The global point-of-care glucose testing market is driven by an increase in diabetes incidence rates, a rise in the geriatric population, technological advancements in diabetes monitoring devices, and an increased prevalence of diabetes risk factors. However, the accuracy concerns of glucose...
PR Newswire
20/06/2023

Santhera Grants Exclusive North America License for Vamorolone to Catalyst…

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held today at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Santhera will receive USD 90million upfrontat closing (USD 75 million in cash and USD 15 million equity investment) , an additional USD 10 million upon U.S. FDA approval of vamorolone in Duchenne muscular dystrophy (DMD) plus USD 26 million to pay approval ...
Nasdaq GlobeNewswire
20/06/2023

The Art of Luxury in Baby Care with Bubble Baby Bed - The Crown Jewel in Luxury…

"The Bubble Baby Bed isn't just a crib; it's a testament to luxury, safety, and avant-garde artistry, effortlessly matching any home's grandeur," says Agiyan. "The Bubble Baby Bed isn't just a crib; it's a testament to luxury, safety, and avant-garde artistry, effortlessly matching any home's grandeur," says Agiyan. The transparent crib design, favoured by royal households, allows caregivers to monitor their precious ones effortlessly. Its mattresses, designed with a 3D…
PR Newswire
20/06/2023

Subang Jaya Medical Centre Awarded Frost & Sullivan's Company of the Year Award…

SJMC's Cancer & Radiosurgery Centre has been gaining a strong reputation since 2002 and has evolved to become a leader in regional cancer care. The center offers a full complement of services designed to address all aspects of cancer treatment for both adult and pediatric patients through a multidisciplinary and integrated approach. SJMC is among the first hospitals in Malaysia to routinely measure the performance of its cancer care services, with the results comparable with leading centers…
PR Newswire
20/06/2023

Alopecia Areata Market to Show Positive Growth at a CAGR of 26.3% During the…

Key Takeaways from the Alopecia Areata Market Report Key Takeaways from the Alopecia Areata Market Report Discover which therapies are expected to grab the major alopecia areata market share @Alopecia Areata Market Report Alopecia Areata Overview Alopecia areata is a common autoimmune skin disease that causes hair loss on the scalp, face, and, in rare cases, other parts of the body. The afflicted hair follicles are targeted by a person's immune system, resulting in the hair...
PR Newswire
19/06/2023
Altri  Comunicati